Marijuana use in models for health outcomes.

Am J Med

Department of Clinical Pharmacy, Pharmaceutical Economics & Policy, Leonard Schaeffer Center for Health Policy & Economics, University of Southern California, University Park Campus, Los Angeles.

Published: March 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2014.07.039DOI Listing

Publication Analysis

Top Keywords

marijuana models
4
models health
4
health outcomes
4
marijuana
1
health
1
outcomes
1

Similar Publications

Pharmacological modulation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) through dual GIP/GLP-1 receptor agonists, commonly used for diabetes and obesity, shows promise in reducing alcohol consumption. We applied drug-target Mendelian randomization (MR) using genetic variation at these loci to assess their long-term effects on problematic alcohol use (PAU), binge drinking, alcohol misuse classifications, liver health, and other substance use behaviors. Genetic proxies for lowered BMI, modeling the appetite-suppressing and weight-reducing effects of variants in both the GIPR and GLP1R loci ("GIPR/GLP1R"), were linked with reduced binge drinking in the primary (β = -0.

View Article and Find Full Text PDF

Masataka et al.'s cannabis gateway study misrepresents the 43.8% probability of cannabis users transitioning to illegal drugs as "rare," and misuses regression via the Table 2 Fallacy.

View Article and Find Full Text PDF

Association Between Cannabis Use and Neuropsychiatric Disorders: A Two-sample Mendelian Randomization Study.

Alpha Psychiatry

August 2025

Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, 130021 Changchun, Jilin, China.

Background: The progressive legalization and widespread use of cannabis has led to its use as a treatment for certain neuropsychiatric disorders. Traditional epidemiological studies suggest that cannabis use has an effect on some neurocognitive aspects. However, it is unclear whether cannabis use is causally related to common neuropsychiatric disorders.

View Article and Find Full Text PDF

Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco.

J Cannabis Res

September 2025

Department of EconomicsMA in Applied Economics, Lebanese American University, P.O. Box: 13-5053, Beirut, Lebanon.

Amidst the global shift toward cannabis legalization, this study examines medical cannabis (MC) sales as an indicator of economic activity and innovation. It explores associations between MC sales, and variables including tobacco use, alcohol consumption, amphetamine, cocaine and cannabis prevalence, and gross domestic product (GDP), using a fixed effects (FE) panel regression model. It also evaluates associations between cannabis legalization and MC sales over time using a dynamic Difference-in-Differences (DiD) approach with multiple time periods.

View Article and Find Full Text PDF

UGT2B7-mediated drug-drug interaction between cannabinoids and hydromorphone.

Drug Metab Dispos

July 2025

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Division of Molecular Biosciences, Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York

Hydromorphone is a highly potent opioid used to treat severe chronic pain. It is metabolized primarily by UDP-glucuronosyltransferase (UGT)2B7 to form the inactive hydromorphone-3-glucuronide. Given that previous studies have shown that the major cannabinoids, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), inhibit several UGT enzymes, the objective of the present study was to determine the inhibitory potential of major cannabinoids and their metabolites on UGT-mediated hydromorphone metabolism.

View Article and Find Full Text PDF